MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
Key Highlights
- ➤Full-year 2026 revenue guidance rises to approximately $34 million
- ➤Q3 core business revenue approximately $8.1 million, up 26% year-over-year
- ➤SPL-related revenue exceeds $1.0 million, including a $1.0 million milestone
- ➤2026 core revenue guidance rises to approximately $28 million
- ➤Two pivotal SPL-partner trials could potentially reach approval as early as next year
Expert Statements
Maher Masoud, President and CEO of MaxCyte
“Preliminary third quarter and total second half revenue is ahead of our expectations, and we updated our core business revenue guidance to reflect approximately 15% year-over-year growth in the second half of 2026.”
Maher Masoud, President and CEO of MaxCyte
“We entered into 2026 with the goal of getting back to growth in the second half and we are very encouraged by our return to double-digit growth, with meaningful outperformance in the third quarter driven by accelerated instrument purchasing from a large customer, which we originally anticipated to occur in the fourth quarter.”
Maher Masoud, President and CEO of MaxCyte
“In addition, we raised our SPL Program-related revenue guidance after recognizing a milestone from one of our SPL partners, our second milestone achieved in 2026.”
Maher Masoud, President and CEO of MaxCyte
“We are now supporting more late-stage clinical programs under our SPL partnerships than ever before with two pivotal trials that have potential for approval as early as next year.”
Maher Masoud, President and CEO of MaxCyte
“Overall, we remain focused on executing on our strategic priorities, strengthening our position as a leading enabling technology partner in cell and gene therapy, and building a foundation for sustainable long-term growth.”
ROCKVILLE, Md., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced preliminary revenue for the third quarter ended September 30, 2026 and raised its 2026 revenue guidance.
Preliminary Third Quarter Revenue * Core business revenue of approximately $8.1 million in the third quarter of 2026, an increase of 26% compared to the third quarter of 2025. * Strategic Platform License (SPL) Program-related revenue of more than $1.0 million, including milestone revenue of $1.0 million received in the third quarter of 2026. MaxCyte will report royalty revenue with its full financial results on November 10, 2026. MaxCyte’s third quarter results are preliminary, unaudited and subject to change in connection with the completion of MaxCyte’s quarterly closing process and review procedures. As a result, these preliminary results may differ from the actual results that will be reflected in MaxCyte’s consolidated financial statements for the quarter ended September 30, 2026.
Get started
Create a free account to read the full story.